thymoma type AB

Summary

thymoma type AB (MONDO:0016975) is a disease. A subtype of thymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	thymoma type AB
Mondo ID	MONDO:0016975
EFO	EFO:1000582
Orphanet	263324
DOID	DOID:3280
NCIT	C6885
UMLS	C1266092
MedGen	220414
GARD	0020894
Is cancer (heuristic)	no

Also known as: mixed type thymoma · primary thymic epithelial neoplasm type AB · primary thymic epithelial tumor type AB · primary thymic epithelial tumour type AB · thymoma type AB

Data availability: 3 cell lines.

Disease family

This is a subtype of thymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › thymus neoplasm › thymic epithelial neoplasm › thymoma › thymoma type AB

Related subtypes (7): encapsulated thymoma, thymoma type A, combined thymoma, invasive malignant thymoma, noninvasive malignant thymoma, thymoma, familial, thymoma type B

Subtypes (1): malignant type AB thymoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.